Why is the Polynovo share price rising while other ASX 200 stocks are plummeting?

Polynovo shares are avoiding today's market sell-off.

Key points
  • Polynovo shares are up today amid a widespread market sell-off 
  • There have been no announcements from the company today
  • Recent insider buying action might be buoying investor sentiment 

Despite most ASX companies being in the red today, the Polynovo Ltd (ASX: PNV) share price is rising.

During late afternoon trade, the medical device company's shares are changing hands for $1.21, up 4.76%.

In comparison, the S&P/ASX 200 Index (ASX: XJO) is plummeting by 4.33% to 6,631 points.

A smug young man points to his chest feeling proud that he invested in Polynovo shares which are rising today amid a market sell-off

Image source: Getty Images

Polynovo defies ASX market sell-off

Polynovo investors are shrugging off the wider market slump today.

The company hasn't made any price-sensitive announcements since its third quarter trading update in early April.

However, insider buying action among senior Polynovo managers has likely propped up the share price and overall sentiment.

In particular, Polynovo chairperson David Williams made a series of purchases from the start of May totalling more than $5 million.

Not only did Williams take advantage of the share price weakness but he's been averaging down his cost position.

In total, Williams now has more than 24.59 million Polynovo shares spread across a series of portfolios.

The number of buy-ins conducted tells us that Williams believes the company's shares are trading at an attractive price. This seems to have resonated with investors, which could be why Polynovo is defying the ASX sell-off today.

It is worth nothing that at the start of May, Polynovo shares hit a 52-week low of 83.5 cents.

Polynovo share price summary

Since this time last year, the Polynovo share price has fallen by 56%.

Year-to-date it has fared better, but you'd still be looking at a loss of 25% if you invested at the start of 2022.

Based on today's share price, Polynovo presides a market capitalisation of approximately $764.25 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the ResMed share price a cheap buy?

I look at what the next few years of earnings growth could mean for today’s valuation.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Expert names 'undervalued' ASX 200 healthcare stock to buy today

A top fundie expects more outperformance from this resurgent ASX healthcare share.

Read more »

A gavel is placed on a stand on a desk with a legal representative wearing a suit in the background.
Healthcare Shares

Cochlear shares fall as investors face another setback

Cochlear shares are back in the red.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the Medibank share price a buy for its 6% dividend yield?

This business is offering very healthy dividends.

Read more »

Senior man looking at his laptop and pondering something.
Healthcare Shares

Could Mesoblast shares rise over 100% in 12 months?

Bell Potter has given its view on this stock.

Read more »

Two scientists analysing results on a computer screen.
Healthcare Shares

$10,000 invested in Pro Medicus and CSL shares 3 years ago is now worth…

Was I better off investing $10,000 into Pro Medicus or CSL shares three years ago?

Read more »

A share market investment manager monitors share price movements on his mobile phone and laptop
Healthcare Shares

Fund managers are loading up on CSL shares. Here's why

CSL is attracting renewed interest from fundies.

Read more »

Happy businessman fist pumping while looking at a tablet.
Healthcare Shares

Mesoblast wins FDA nod for new Ryoncil potency test

Mesoblast gets FDA approval for a new Ryoncil potency assay, aiming to ensure quality and support product expansion.

Read more »